Related Experiment Video
Updated: Aug 6, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay
B J Wahlberg1, D R Burholt, P Kornblith
1Department of Pharmacology, University of Pittsburgh School of Medicine, 15213, Pittsburgh, PA, USA.
Abstract:
Natural killer (NK) cells are spontaneously cytotoxic immune effector cells with the ability to selectively destroy tumor cells without harming normal cells. To perform this function, NK cells utilize two main cytotoxicity pathways, the well known perforin/granzyme-mediated secretory/necrotic killing and the recently defined TNF family ligand-mediated non-secretory/apoptotic killing. The former mechanism is manifested mainly against a few cultured leukemia cell targets, while the latter mediates killing against a large variety of tumor cell targets. Therefore, the biological role and significance of these mechanisms might be different. The NK cell-mediated necrotic killing has been reliably and selectively measured in humans by the standard 4-h 51Cr release assay (CRA) against K562 myeloid leukemia cell targets. However, no standardized high throughput assay is available for testing the NK cell-mediated apoptotic killing. Here, we introduce the modified MCA as a convenient method for measuring perforin/granzyme-independent NK cell-mediated apoptotic killing. The assay is performed in microwells of Terasaki tissue culture microtest plates, using adherent tumor cell targets, which are selectively susceptible to non-secretory/apoptotic killing and resistant to secretory/necrotic killing mediated by NK cells. Target cells are plated in microwells and incubated overnight to adhere to the plastic surface and to regenerate cell surface-bound TNF family receptors. Following this adherence, target cells are co-incubated with freshly isolated human peripheral blood mononuclear leukocytes (PBMNL) or purified subpopulations of immune cells for 24 h in various effector/target (E/T) ratios. During this incubation, dead target cells become non-adherent and are removed by washing the wells. Remaining adherent (viable) target cells are fixed, stained and optically counted. A notable dose-dependent (peak at 200:1 E/T ratio), time-dependent (peak at 24 h of incubation) and donor-dependent killing of tumor cells was consistently and reproducibly induced by PBMNL of normal donors. Using purified subpopulations of immune cells, it was demonstrated that among PBMNL, CD3(-)CD56(+)CD16(+) mature NK cells are the only mediators of tumor cell killing in MCA, as well as in CRA. Comparative studies of NK activity detected by MCA and CRA, performed with PBMNL from normal individuals and breast cancer patients, showed no significant correlation between the cytotoxicities measured in the two assays. In addition, while NK activity measured in CRA was normal in most breast cancer patients, NK activity assessed in MCA was decreased in a large majority of the patients. Thus, MCA is a sensitive NK assay, which is biologically different from CRA, and may be clinically relevant. MCA has also a higher throughput, and is more practical and economical than CRA.
Insights
Natural killer (NK) cells kill tumor cells via necrotic or apoptotic pathways. A new modified cell assay (MCA) measures apoptotic killing, revealing reduced NK cell activity in breast cancer patients, unlike standard assays.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Natural killer (NK) cells are crucial immune cells that eliminate tumor cells through distinct cytotoxic pathways: perforin/granzyme-mediated necrosis and TNF ligand-mediated apoptosis.
- Current methods, like the chromium-51 release assay (CRA), reliably measure necrotic killing but lack standardized, high-throughput assays for apoptotic killing.
- This gap limits the comprehensive assessment of NK cell function, particularly in disease contexts where apoptotic pathways may be more relevant.
Purpose of the Study:
- To introduce and validate a modified cell assay (MCA) for measuring perforin/granzyme-independent, NK cell-mediated apoptotic killing of tumor cells.
- To compare the sensitivity and clinical relevance of MCA with the standard CRA for assessing NK cell activity.
- To investigate NK cell activity in breast cancer patients using both MCA and CRA.
Main Methods:
- The modified cell assay (MCA) utilizes adherent tumor cell targets in microwells, co-incubated with peripheral blood mononuclear leukocytes (PBMNL) for 24 hours.
- Viable, adherent tumor cells are quantified after washing away non-adherent dead cells, allowing measurement of NK cell-induced apoptosis.
- NK cell activity was assessed in parallel using MCA and the standard chromium release assay (CRA) in healthy donors and breast cancer patients.
Main Results:
- The MCA demonstrated dose-dependent, time-dependent, and donor-dependent killing of tumor cells, mediated exclusively by CD3(-)CD56(+)CD16(+) NK cells.
- No significant correlation was found between NK cell activities measured by MCA and CRA in healthy individuals or breast cancer patients.
- While CRA showed normal NK activity in most breast cancer patients, MCA revealed significantly decreased NK cell-mediated apoptotic killing in a majority of patients.
Conclusions:
- The modified cell assay (MCA) provides a sensitive, high-throughput, and practical method for measuring NK cell-mediated apoptotic killing.
- MCA assesses a distinct biological mechanism of NK cell cytotoxicity compared to CRA, highlighting its potential clinical relevance.
- The reduced NK cell apoptotic activity observed via MCA in breast cancer patients suggests this pathway's importance in cancer immunology and diagnostics.

